MME and hydrops fetalis: In addition to traditional medications to control HF, sacubitril, an angiotensin receptor–neprilysin inhibitor (ARNI), is currently recommended for patients with HF due to its significant benefits in reducing cardiovascular mortality and hospitalization [93].